IDO2 an active enzyme to target in pancreatic cancer EurekAlert (press release), DC - (PHILADELPHIA) An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, ...
New Cancer Treatment Shrinks Pancreatic Tumor MarketWatch - Nov 23, 2008 NASHVILLE, Tenn., Nov 24, 2008 /PRNewswire via COMTEX/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. ...
Drive to target specific cancers The Press Association - "The outcomes of these discussions will form the basis of major new initiatives to tackle both pancreatic and oesophageal cancer - and a commitment to ...
Education notes Sheboygan Press, WI - Nov 30, 2008 Cleveland Elementary and NEW Montessori schools showed their support during Pancreatic Cancer Awareness Month by wearing the color purple. ...
Source: Google News
Recent News and Articles on the Keywords: new + cancer + pancreatic Related to the article below (Last Update: 8/7/2008)
New Gene Therapy Kills Pancreatic Cancer Cells Science Daily (press release) - Aug 5, 2008 The results indicated that the CGT approach not only prevented pancreatic cancer growth and progression, but it also effectively killed established tumors, ...OTC:CTHP - BIT:MLM
City's Docs in Pounds 5m War on Cancer RedOrbit, TX - Liverpool is to be one of only three cities in the country to receive the windfall for a new Biomedical Research Unit (BRU) to specialise in pancreatic and ...
Researchers Unveil Vital Key To Cancer Science Daily (press release) - Knowing the structure is critical for the design of new kinase inhibitors as therapeutic agents, an area of enormous importance to the pharmaceutical ...
Combination Therapy Kills Pancreatic Cell Tumors In Mice ... Best Syndication, CA - Aug 6, 2008 (Best Syndication News) There is new hope for those suffering from Pancreatic Cancer, according to researchers from the Virginia Commonwealth University ...
Doctor aces cancer Concord Monitor, NH - Then he smashed an overhead winner, an exclamation point on his successful battle against pancreatic cancer. "I don't think I've ever bragged about it," ...
12:05 pm - UAMS Recognized for Cancer Work KARK, Little Rock - UAMS was recognized as a Blue Distinction Center for six types of cancer: bladder cancer, brain cancer ? primary, gastric cancer, liver cancer, pancreatic...
Wilheit joins the Georgia Cancer Coalition Board Access North Georgia, GA - "Like everyone I know, cancer has touched my family: my father died of pancreatic cancer in 1990, only three months after being diagnosed," says Mr. Wilheit ...
[PDF]NEW FUNCTIONS FOR THE MATRIX METALLOPROTEINASES IN CANCER PROGRESSION - M Egeblad, Z Werb - Nature Reviews Cancer, 2002 - microarray.princeton.edu ... They are kept inactive by an interaction NEW FUNCTIONS FOR THE MATRIX
METALLOPROTEINASES IN CANCER PROGRESSION Mikala Egeblad and Zena Werb ... -
Cyclooxygenase-2 Expression Is Up-Regulated in Human Pancreatic Cancer 1 - ON Tucker, AJ Dannenberg, EK Yang, F Zhang, L Teng … - Cancer Research, 1999 - AACR ... In the United States, 25,000 new cases of pancreaticcancer are diagnosed annually
(1) . Pancreaticcancer now ranks fourth and fifth as a cause of cancer...
Improving the evaluation of new cancer treatments: challenges and opportunities - ML Rothenberg, DP Carbone, DH Johnson - cancer. J, 2001 - chem.missouri.edu ... designed to treat advanced pancreaticcancer (gemcitabine) 2 ... hormone-sensitive breast cancer (anastrozole, fulvestrant ... that the paceof new agent development ...
Source: Google Scholar
Pancreatic cancer: new treatment reduces the size of tumors and lowers the risk of local recurrence of the disease
A new treatment for pancreatic cancer developed by researchers of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center substantially reduces the size of tumors and lowers the risk of local recurrence of the disease.
Fifty percent of patients in the study responded to therapy -- one of the highest response rates ever seen with pancreatic cancer.
Results of the study are published in the Annals of Surgical Oncology.
Researchers, led by J. Marc Pipas, were able to reduce the size of tumors so significantly that a number of patients who previously had been categorized as borderline or inoperable could have their tumors surgically removed.
Surgery, and the complete removal of the tumor, is the only curative hope for people with pancreatic cancer, the fourth leading cause of cancer death in the U.S., according to the National Cancer Institute ( NCI ).
NCI estimates that of the 32,180 new cases of pancreatic cancer in 2005, 31,800 will die.
The overall five-year survival rate for pancreatic cancer is only 4%, but for patients whose tumors can be completely removed, long-term survival jumps to 18-24%. Detecting the tumor in an early stage is crucial, but pancreatic cancer has few symptoms and is often diagnosed only after the cancer has grown into surrounding tissue or metastasized, making surgery impossible.
" The only way to cure these tumors is to remove them completely," explains Pipas. " You try to do something to make sure there is no microscopic disease left. If you can't remove it, the prognosis is poor."
Traditional treatment for pancreatic cancer is surgery followed by chemotherapy and radiation.
The treatment Pipas developed reverses the treatment steps. He administers chemotherapy and radiation in combination first, in order to reduce the size of the tumor and increase the possibility of surgery.
The reverse treatment regimen results in many tumors previously considered borderline or inoperable shrinking to a size where they could be surgically removed.
In the Norris Cotton Cancer Center trial, 24 patients were treated with short course, high dose chemotherapy of Docetaxel and Gemcitabine, followed by a combination of radiation and twice-weekly low-dose Gemcitabine.
Chemotherapy doses in this trial were higher than previously attempted.
Results showed that 50% of tumors shrank by at least a third, including complete disappearance of a tumor in a patient who previously had been judged inoperable.
No tumors progressed during treatment.
The ability to shrink a pancreatic tumor is important because in order to eradicate the cancer, the tumor must be small enough to be completely removed without damaging major blood vessels surrounding the pancreas.
Seventeen patients in the study underwent surgery, including nine previously considered inoperable or borderline operable.
Subsequent follow-up showed that no patient whose tumor was surgically removed had a local recurrence of the disease, and no patient whose disease was considered inoperable had local progression.
In a new study, Pipas is using Gemcitabine and radiation in combination with Cetuximab ( Erbitux ), an antibody treatment.
